Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Nerdwallet Inc (NRDS) Price & Performance

Charles River Laboratories Intl. IncTrade
Nerdwallet IncTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Nerdwallet Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $232.53 (market cap $11.14B), while Nerdwallet Inc trades at $9.17 (market cap $616.53M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 18.1× Nerdwallet Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals.

CRLNRDS
Market Cap
$11.14B$616.53M
Sector
HealthFinancials
52-Week High
$233.60$15.93
52-Week Low
$145.57$7.58
Enterprise Value
$14.00B$530.83M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Nerdwallet Inc

NerdWallet (NRDS) trades at $9.49, up 0.21% today, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported revenue of $836.6M in 2025, with net income of $48.7M and a net margin of 5.82%, showing a clear turnaround from losses in prior years. Recent earnings beats, including Q1 2026 EPS of $0.29 versus $0.25 expected, underscore operational strength. Analyst consensus is bullish with a $12.75 price target, implying 34% upside.

The outlook is positive given valuation multiples like a P/E of 10.2 and EV/EBITDA of 3.87, which appear attractive relative to growth. Key risks include reliance on search-driven traffic and macroeconomic sensitivity. Continued execution on revenue diversification and cost control supports further upside, but investors should monitor competitive pressures and consumer spending trends.

Returns comparison

Trailing returns across standard periods

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Nerdwallet Inc

Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.

Read more on NRDS